What question did this study set out to answer?

To review the logistical requirements, quality assurance standards, and advanced manufacturing platforms necessary for clinical-grade CAR-T cell production.

January 1, 2016SHILAP Revista de lepidopterologíaOpen Access

Clinical manufacturing of CAR T cells: foundation of a promising therapy

View Full Paper

Ask AI

Bookmark

To review the logistical requirements, quality assurance standards, and advanced manufacturing platforms necessary for clinical-grade CAR-T cell production.
Evaluated current platforms and automated processing pipelines used for clinical-grade autologous CAR-T cell expansion.
Analyzed quality-by-design requirements, logistical constraints, and regulatory standards across individual manufacturing steps.
Identifies integrated, step-by-step quality control as essential across all stages of cell isolation, gene transfer, and expansion to ensure clinical efficacy.
Highlights unresolved challenges in batch-to-batch standardization, product characterization, and operational scaling that impede widespread commercialization.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Narrative review outlines clinical manufacturing platforms and regulatory hurdles for chimeric antigen receptor T cells in cancer, highlighting bottlenecks in standardizing commercial cell production.

Cite This Study

Wang et al. (2016) studied this question.

synapsesocial.com/papers/69d7ec85f39344339dd18da2 https://doi.org/10.1038/mto.2016.15

View Full Paper

Ask AI

Bookmark

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Key Points

Discussion

Implication

Cite This Study

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider